2485861-07-0
Chemical Structure
Rocbrutinib
Synonym(s): LP-168
- CAS No.: 2485861-07-0
- Formula:C42H51N9O5
- Molecular Weight:761.91
InChIKey: OYJVFTNYBWVQHA-SANMLTNESA-N
SMILES: O=C1C2=CC(CC(C)(C3)C)=C3N2CCN1C4=C(C(C(N=C5NC6=CC(NC(C=C)=O)=C(N7[C@H](CN(C8CCOCC8)CC7)C)C=C6)=CN(C)C5=O)=CC=N4)CO
Biological Activity: Rocbrutinib is an orally available, highly selective Bruton's tyrosine kinase (BTK) inhibitor, with an IC50 of 0.11 nM against wild-type BTK and an IC50 of 1.0 nM against C481S-mutated BTK. Rocbrutinib reduces the viability of leukemia cells, induces cytotoxicity and inhibits cell migration. Rocbrutinib can be used in research related to chronic lymphocytic leukemia, non-Hodgkin's lymphoma and mantle cell lymphoma[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Rocbrutinib | 99.76% | Rocbrutinib is an orally available, highly selective Bruton's tyrosine kinase (BTK) inhibitor, with an IC50 of 0.11 nM against wild-type BTK and an IC50 of 1.0 nM against C481S-mutated BTK. Rocbrutinib reduces the viability of leukemia cells, induces cytotoxicity and inhibits cell migration. Rocbrutinib can be used in research related to chronic lymphocytic leukemia, non-Hodgkin's lymphoma and mantle cell lymphoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Britten Gordon BS, et al. Targeting Covalent and Non-Covalent Btki-Resistant CLL Using the Dual Irreversible/Reversible 4 th Generation BTK Inhibitor LP-168. Blood (2025) 146 (Supplement 1): 1532.
- [2]. Britten Gordon, et al. Targeting BTKi-resistant CLL using the dual irreversible/reversible 4th generation BTK inhibitor rocbrutinib. Blood (2025) 146 (Supplement 1): 1532.
